至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

biorxiv. 2020-07; 
Flavia Chiuppesi, Marcela d'Alincourt Salazar, Heidi Contreras, Vu H Nguyen, Joy Martinez, Soojin Park, Jenny Nguyen, Mindy Kha, Angelina Iniguez, Qiao Zhou, Teodora Kaltcheva, Roman Levytskyy, Nancy D Ebelt, Tae Hyuk Kang, Xiwei Wu, Thomas Rogers, Edwin R Manuel, Yuriy Shostak, Don J Diamond, Felix Wussow
Products/Services Used Details Operation
GenParts™ DNA Fragments The sMVA fragments were produced and assembled by Genscript using chemical Get A Quote

摘要

Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We developed a novel vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we used this novel vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. Mice immunized with these sMVA vectors developed robust SARS-CoV-2 antigen-specific humoral and cellular immune respons... More

关键词